{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:10:47Z","timestamp":1791277847471,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["ATVB"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:p>Dabigatran is a highly selective, reversible, and potent thrombin inhibitor and is orally available as the prodrug, dabigatran etexilate. It has shown antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action and predictable pharmacodynamic response. Peak plasma concentrations of dabigatran occur 1 to 2 hours after ingestion of the prodrug. The terminal half-life of dabigatran is 12 to 14 hours in elderly volunteers. Dabigatran is not metabolized by cytochrome P450 isoenzymes and does not interact with food. Dabigatran has a low potential for drug-drug interactions and is predominantly renally excreted. Dabigatran etexilate as chronic therapy effectively prevents the recurrence of venous thromboembolism and cardioembolic stroke. For the first time, it has been demonstrated clinically that there may be an effective and safe alternative to warfarin.<\/jats:p>","DOI":"10.1161\/atvbaha.110.203604","type":"journal-article","created":{"date-parts":[[2010,7,30]],"date-time":"2010-07-30T03:13:58Z","timestamp":1280459638000},"page":"1885-1889","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":179,"title":["Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin"],"prefix":"10.1161","volume":"30","author":[{"given":"Wolfgang G.","family":"Eisert","sequence":"first","affiliation":[{"name":"From the Clinical Development and Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, Germany (W.G.E., A.C.); Departments of Medicinal Chemistry (N.H.), Drug Metabolism and Pharmacokinetics (J.S.), Pulmonary Research (W.W.), Drug Discovery Support (J.v.R.), Boehringer Ingelheim Pharma GmbH &amp; Co KG, Biberach, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Hauel","sequence":"additional","affiliation":[{"name":"From the Clinical Development and Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, Germany (W.G.E., A.C.); Departments of Medicinal Chemistry (N.H.), Drug Metabolism and Pharmacokinetics (J.S.), Pulmonary Research (W.W.), Drug Discovery Support (J.v.R.), Boehringer Ingelheim Pharma GmbH &amp; Co KG, Biberach, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Stangier","sequence":"additional","affiliation":[{"name":"From the Clinical Development and Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, Germany (W.G.E., A.C.); Departments of Medicinal Chemistry (N.H.), Drug Metabolism and Pharmacokinetics (J.S.), Pulmonary Research (W.W.), Drug Discovery Support (J.v.R.), Boehringer Ingelheim Pharma GmbH &amp; Co KG, Biberach, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wienen","sequence":"additional","affiliation":[{"name":"From the Clinical Development and Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, Germany (W.G.E., A.C.); Departments of Medicinal Chemistry (N.H.), Drug Metabolism and Pharmacokinetics (J.S.), Pulmonary Research (W.W.), Drug Discovery Support (J.v.R.), Boehringer Ingelheim Pharma GmbH &amp; Co KG, Biberach, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[{"name":"From the Clinical Development and Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, Germany (W.G.E., A.C.); Departments of Medicinal Chemistry (N.H.), Drug Metabolism and Pharmacokinetics (J.S.), Pulmonary Research (W.W.), Drug Discovery Support (J.v.R.), Boehringer Ingelheim Pharma GmbH &amp; Co KG, Biberach, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"van Ryn","sequence":"additional","affiliation":[{"name":"From the Clinical Development and Medical Affairs, Boehringer Ingelheim GmbH, Ingelheim, Germany (W.G.E., A.C.); Departments of Medicinal Chemistry (N.H.), Drug Metabolism and Pharmacokinetics (J.S.), Pulmonary Research (W.W.), Drug Discovery Support (J.v.R.), Boehringer Ingelheim Pharma GmbH &amp; Co KG, Biberach, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_1_2","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2001.026.12.649378"},{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2006.04.005"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(92)91054-S"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm0109513"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-03-0183"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH07-02-0113"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02526.x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.019083"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02899.x"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847010-00005"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/11318170-000000000-00000"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-11-0758"},{"key":"e_1_3_3_15_2","first-page":"756","volume":"42","year":"2003","unstructured":"Wahlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet. 2003; 42: 756\u2013764.","journal-title":"Clin Pharmacokinet"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1076029609343004"},{"key":"e_1_3_3_17_2","first-page":"411","volume":"48","year":"2008","unstructured":"Stangier J, St\u00e4hle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008; 48: 411\u20131419.","journal-title":"J Clin Pharmacol"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256595"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006297228"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02667.x"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005274550"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847050-00001"},{"key":"e_1_3_3_23_2","first-page":"148.","volume":"93","year":"2008","unstructured":"van Ryn J, Ruehl D, Priepke H, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate (abstract 0370). Haematologica. 2008; 93 (suppl 1): 148.","journal-title":"Haematologica"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00890.x"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.01100.x"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.06.034"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(00)00399-6"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2009.07.019"}],"container-title":["Arteriosclerosis, Thrombosis, and Vascular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/ATVBAHA.110.203604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T22:54:00Z","timestamp":1715554440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/ATVBAHA.110.203604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1161\/ATVBAHA.110.203604"],"URL":"https:\/\/doi.org\/10.1161\/atvbaha.110.203604","relation":{},"ISSN":["1079-5642","1524-4636"],"issn-type":[{"value":"1079-5642","type":"print"},{"value":"1524-4636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"2010-07-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}